We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (NILACH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01683656
Recruitment Status : Terminated (Withdrawal of IMP from the market. Data on risk-benefit ratio pending.)
First Posted : September 12, 2012
Last Update Posted : March 15, 2013
University Hospital, Geneva
Swiss National Science Foundation
Fondation Ernest Boninchi
Swiss Heart Foundation
Information provided by (Responsible Party):
Calmy Alexandra, University Hospital, Geneva

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Estimated Primary Completion Date : July 2014
  Estimated Study Completion Date : July 2014